Chemomab Therapeutics (CCMB) H.C. Wainwright 27th Annual Global Investment Conference summary

Key presentations and announcements

• Presented positive phase II results for nebokitug, a first-in-class monoclonal antibody targeting CCL24, in primary sclerosing cholangitis (PSC).

• Nebokitug demonstrated significant anti-inflammatory and anti-fibrotic effects, meeting both primary (safety) and secondary (efficacy) endpoints in the phase II study.

• The 20 mg/kg dose was selected for phase III, focusing on patients with moderate to advanced PSC.

• High patient compliance observed, with 93% of eligible patients entering the open-label extension for up to 48 weeks.

• FDA alignment achieved for a single pivotal phase III study, with plans to initiate soon and pursue full approval.

Industry analysis and competitive landscape

• PSC is a rare liver disease with no approved treatments; current therapies only address symptoms, not disease progression.

• Nebokitug is positioned as the only disease-modifying therapy in development for PSC, with potential to become the first approved drug for this indication.

• Estimated commercial opportunity exceeds $1 billion annually due to high unmet need and premium pricing potential.

• Strong interest from top-tier investors and potential strategic partners based on phase II results.

Forward-looking statements and development plans

• Phase III study will evaluate clinical events beyond liver transplant and death, enabling a more feasible and timely trial.

• Ongoing discussions with partners to support phase III initiation and commercialization.

• Nebokitug's dual mechanism may have applications in other fibrotic diseases, with supporting data in systemic sclerosis and IPF.

• Long-term safety and efficacy data support continued development and regulatory advancement.